表紙
市場調查報告書

臨床實驗的全球市場:成長,趨勢,預測

Clinical Trials Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 390668
出版日期 內容資訊 英文 117 Pages
商品交期: 2-3個工作天內
價格
臨床實驗的全球市場:成長,趨勢,預測 Clinical Trials Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年02月01日內容資訊: 英文 117 Pages
簡介

本報告提供全球臨床實驗 市場相關分析,市場基本結構和促進、阻礙因素,市場規模趨勢預測 (今後6年份),各相位、各臨床實驗計劃、各地區的詳細趨勢,市場競爭環境 (近來的資本交易的動向等),主要企業的簡介,今後的市場機會等相關調查。

第1章 簡介

第2章 分析方法

第3章 摘要整理

第4章 市場動態

  • 市場概要
  • 推動市場要素
  • 阻礙市場要素
  • 產業的向心力:波特的五力分析

第5章 市場區隔

  • 各階段
    • 第一階段
    • 第二階段
    • 第三階段
    • 第四階段
  • 各設計 (計劃)
    • 治療研究
      • 隨機化比較實驗
        • 雙盲檢隨機化實驗
        • 單盲檢隨機化實驗
        • 非盲檢隨機化實驗
      • 適應的臨床實驗
      • 非隨機化比較實驗
    • 觀察研究
      • 世代研究
      • 病例對照研究
      • 橫斷性研究
      • 地區相關研究 (生態學研究)
  • 各地區
    • 北美 (美國,加拿大,墨西哥)
    • 歐洲 (德國,英國,法國,義大利,西班牙等)
    • 亞太地區 (中國,日本,印度,澳洲,韓國等)
    • 中東、非洲 (波灣合作理事會 (GCC) 各國,南非等)
    • 南美 (巴西,阿根廷等)

第6章 競爭環境

  • 企業簡介
    • Clinipace
    • Laboratory Corporation of America
    • Eli Lilly and Company
    • ICON PLC
    • Novo Nordisk AS
    • PAREXEL International Corporation
    • Pfizer Inc.
    • Pharmaceutical Product Development LLC
    • IQVIA
    • F. Hoffmann-La Roche Ltd
    • Sanofi
    • Wuxi AppTec

第7章 市場機會及未來趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 49264

Market Overview

The major factors found propelling the growth of the market include the high demand for clinical trials in emerging markets, high R&D spending of the pharmaceutical industry, an increasing prevalence of diseases, and the focus on rare diseases and multiple orphan drugs in the pipeline.

The market is growing at a robust pace, owing to the advancements in healthcare and growing patented new chemical entities (NCE) indicated for various health conditions.

It has also been found that there are a large number of unmet clinical needs in emerging countries, due to the prevalence of infectious and tropical diseases in the region. Owing to these, a large number of the population participate in clinical trials to access high-quality healthcare free of cost. India and China have the highest prevalence rates for metabolic disorders, due to the increasing population, combined with the prevalence of insulin resistance, hyperlipidemia, and obesity.

In addition, government initiatives have also motivated the small, medium, and large players to enter into orphan drug development. Thus, there are multiple drugs in the pipeline. As a result, Novartis, GlaxoSmithKline, and Pfizer (among others) have entered this field. It has also been found that the clinical trials market has taken bigger strides in the developing countries of Asia-Pacific and the Middle East and there is still very less development in the market.

Scope of the Report

As per the scope of the report, clinical trials are experiments that are conducted under clinical research and follow a regulated protocol. These experiments are primarily performed to obtain data regarding the safety and efficacy of newly developed drugs. Clinical trial data is mandatory for drug approval, as well as for it to be introduced in the market. These trials are performed under three phases (I, II, and III), which depends upon various factors. This process is not only expensive, but also time consuming, and requires expertise at all stages.

Key Market Trends

Phase III is the Largest Segment Under Phases that is Expected to Grow During the Forecast Period

The market is expected to be dominated by Phase III, with Phase I expected to witness the fastest growth. Phase III is one of the most critical phases assessing the effectiveness of the new intervention, as well as its value in clinical practice. The Phase I trial in the market studied is also expected to grow at a steady rate, due to the increasing number of investigative new drug (IND) applications filed. The government initiatives in emerging economies for the promotion of drug discovery and continuous technological innovations are expected to propel the market growth.

North America has been Reported with the Largest Growth that is Expected to Follow the Same Trend over the Forecast Period

North America dominated the overall market, owing to the presence of big outsourcing firms and increasing R&D in the region. However, increasing R&D investments and an increasing demand for drug development are the major factors responsible for the market emergence in the United States.

Competitive Landscape

The major pharmaceutical companies are found making enormous investments in R&D, especially in the emerging nations, in order to gain opportunities for market growth in the major regions. The strategic partnerships among pharmaceutical companies and the CROs are expected to have a significant impact on the market's growth.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Demand for Clinical Trials in the Emerging Markets
    • 4.2.2 High R&D Expenditure of the Pharmaceutical Industry
    • 4.2.3 Rising Prevalence of Diseases
    • 4.2.4 Focus on Rare Diseases and Multiple Orphan Drugs in the Pipeline
  • 4.3 Market Restraints
    • 4.3.1 Lack of Skilled Workforce Clinical Research
    • 4.3.2 Lower Healthcare Reimbursement in the Developing Countries
    • 4.3.3 Stringent Regulations for Patient Enrollment
  • 4.4 Porter' s Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Phase
    • 5.1.1 Phase I
    • 5.1.2 Phase II
    • 5.1.3 Phase III
    • 5.1.4 Phase IV
  • 5.2 By Design
    • 5.2.1 Treatment Studies
      • 5.2.1.1 Randomized Control Trial
      • 5.2.1.1.1 Double Blind Trial Randomized Trial
      • 5.2.1.1.2 Single Blind Trial Randomized Trial
      • 5.2.1.1.3 Non-blind Randomized Trial
      • 5.2.1.2 Adaptive Clinical Trial
      • 5.2.1.3 Non-randomized Control Trial
    • 5.2.2 Observational Studies
      • 5.2.2.1 Cohort Study
      • 5.2.2.2 Case Control Study
      • 5.2.2.3 Cross Sectional Study
      • 5.2.2.4 Ecological Study
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East & Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East & Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Clinipace
    • 6.1.2 Laboratory Corporation of America
    • 6.1.3 Eli Lilly and Company
    • 6.1.4 ICON PLC
    • 6.1.5 Novo Nordisk AS
    • 6.1.6 PAREXEL International Corporation
    • 6.1.7 Pfizer Inc.
    • 6.1.8 Pharmaceutical Product Development LLC
    • 6.1.9 IQVIA
    • 6.1.10 F. Hoffmann-La Roche Ltd
    • 6.1.11 Sanofi
    • 6.1.12 Wuxi AppTec

7 MARKET OPPORTUNITIES AND FUTURE TRENDS